Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Systemic Lupus Erythematosus

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Burkitt Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Burkitt Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Burkitt Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Pre-Registration for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Primary CNS Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Primary CNS Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Primary CNS Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Risk adjusted net present value: What is the current valuation of Autolus Therapeutics's Obecabtagene autoleucel?

Obecabtagene autoleucel is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Pre-Registration program in B-Cell Acute Lymphocytic...

Net Present Value Model: Autolus Therapeutics Plc's Obecabtagene autoleucel

Data Insights

Risk adjusted net present value: What is the current valuation of Autolus Therapeutics's Obecabtagene autoleucel?

Obecabtagene autoleucel is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Pre-Registration program in B-Cell Acute Lymphocytic...

Net Present Value Model: Autolus Therapeutics Plc's Obecabtagene autoleucel

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Follicular Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Follicular Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Mantle Cell Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Diffuse Large B-Cell Lymphoma